Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger S Lo

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Cell|January 28, 2017
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaWilly Hugo, Jesse M Zaretsky, Lu Sun, et al.
Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.
Nature Medicine|July 24, 2012
MDM4 is a key therapeutic target in cutaneous melanomaAgnieszka Gembarska, Flavie Luciani, Clare Fedele, et al.
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Nature Cell Biology|September 13, 2016
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylationMin Pan, Michael A Reid, Xazmin H Lowman, et al.
Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.
Nature|July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionRavid Straussman, Teppei Morikawa, Kevin Shee, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Cell Reports. Medicine|November 10, 2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinomaSixue Liu, Hannah M Knochelmann, Shirley H Lomeli, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Cell|January 28, 2017
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaWilly Hugo, Jesse M Zaretsky, Lu Sun, et al.
Cancer|January 23, 2024
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancersAlain P Algazi, James Moon, Christopher D Lao, et al.
Nature Medicine|July 24, 2012
MDM4 is a key therapeutic target in cutaneous melanomaAgnieszka Gembarska, Flavie Luciani, Clare Fedele, et al.
Nature Communications|December 16, 2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanomaJudith Müller, Oscar Krijgsman, Jennifer Tsoi, et al.
Nature Cell Biology|September 13, 2016
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylationMin Pan, Michael A Reid, Xazmin H Lowman, et al.
Journal of Translational Medicine|April 22, 2010
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard, Ramin Nazarian, Qi Wang, et al.
Nature|July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionRavid Straussman, Teppei Morikawa, Kevin Shee, et al.
Cancer Discovery|November 23, 2013
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyHubing Shi, Willy Hugo, Xiangju Kong, et al.
Cell Reports. Medicine|November 10, 2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinomaSixue Liu, Hannah M Knochelmann, Shirley H Lomeli, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Pageof 9